Investigation of the role of 5-HT(1B) and 5-HT(1D) receptors in the sumatriptan-induced constriction of porcine carotid arteriovenons anastomoses

British Journal of Pharmacology

Volumn 127, Issue 2, 1999, Pages 405-412

  De Vries, Peter ^a   Willems, Edwin W ^a   Heiligers, Jan P C ^a   Villalón, Carlos M ^b   Saxena, Pramod R ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

5 HT(1B) (1D) receptors; Arteriovenous anastomoses; BRL15572; Carotid blood flow; Migraine; Pig; SB224289; Sumatriptan

Indexed keywords

2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; AZAPERONE; MIDAZOLAM; NORADRENALIN; PENTOBARBITAL; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN;

ANASTOMOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY; CAROTID ARTERY FLOW; CONDUCTANCE; CONTROLLED STUDY; DOSE RESPONSE; GRAFT OCCLUSION; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SWINE; SYMPATHECTOMY; TACHYCARDIA;

ANIMALS; ARTERIOVENOUS ANASTOMOSIS; BIPHENYL COMPOUNDS; CAROTID ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PIPERAZINES; PIPERIDONES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SPIRO COMPOUNDS; SUMATRIPTAN; SWINE; SYMPATHECTOMY; VAGOTOMY; VASOCONSTRICTOR AGENTS;

EID: 0032986815     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702572     Document Type: Article

References (45)

1. Bouchelet, I., Cohen, Z., Case, B., Seguela, P. & Hamel, E. (1996), Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol., 50, 219-223.
2. 1D antagonists. J. Med. Chem., 37, 2253-2257.
3. 1D receptor antagonist. Br. J. Pharmacol., 118, 85-92.
4. 1D (BRL 15572) receptor antagonists. Eur. J. Pharmacol., 362, 69-72.
5. 1B 1D receptors. Eur. J. Pharmacol., 351, 193-201.
6. 1B 1D, as well as unidentified receptors. In Migraine & headache patho-physiology. eds. Edvinnson L., pp 119-132. London: Martin Dunitz Ltd.
7. Den Boer, M.O., Van Woerkens, L.J., Somers, J.A., Duncker, D.J., Lachmann, B., Saxena, P.R. & Verdouw, P.D. (1993). On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J. Appl. Physiol., 75, 782-789.
8. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan, Br. J. Pharmacol., 102, 323-330.
9. 1B receptor inverse agonist I'-methyl-5-[[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]-carbonyl]-2,3,6,7-tetrahydro-spiro[furo[2,3-f]indole-3,4′-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J. Med. Chem., 41, 1218-1235.
10. Goldstein, J., Dahlöf, C.G.H., Diener, H.C., Olesen, J., Schellens, R., Senard, J.M., Simard, D. & Steiner, T.J. (1996). Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia, 16, 497-502.
11. 1B receptors causes hypothermia in the guinea pig. Eut. J. Pharmacol., 331, 169-174.
12. 1D receptor subtypes. Trends Pharmacol. Sci., 17, 103-105.
13. Heyck, H. (1969). Pathogenesis of migraine. Res. Clin. Stud. Headache, 2, 128.
14. Hoffman, B.B. & Lefkowitz, R.J. (1996). Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. eds. Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. & Goodman Gilman, A., pp 199-248: McGraw-Hill Book Co.
15. Hoyer, D., Clarke, D.E., Fozard, J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J., Saxena, P.R. & Humphrey, P.P. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev., 46, 157-203.
16. 1D receptors mediate inhibition of sympathetic ganglionic transmission in anaesthetized cats. Br. J. Pharmacol., 116, 1715-1717.
17. 3H]alniditan. Mol. Pharmacol., 50, 1567-1580.
18. 1D-immunoreactivity within the human trigemino-cerebro-vascular system: implications for the discovery of new antimigraine drugs. Cephalalgia. 17, 833-842.
19. Macintyre, P.D., Bhargava, B., Hogg, K.J., Gemmill, J.D. & D Hillis, W.S. (1993). Effect of subcutaneous sumatriptan, a selective 5HT, agonist, on the systemic, pulmonary, and coronary circulation. Circulation, 87, 401-405.
20. Martin, G.R. (1994). Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol. Ther., 62, 283-324.
21. 1B, D receptor antagonist GR127935. CNS Drug Rev., 2, 415-428.
22. 11 receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci., 61, 2117-2126.
23. 1D receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 356, 31-320.
24. Saxena, P.R. (1995). Cranial arteriovenous shunting, an in vivo animal model for migraine. In Experimental headache models. eds. Olesen, J. & Moskowitz, M.A., pp. 189-198. Philadelphia: Lippincolt-Raven Publishers.
25. 1-like receptors: a time to bid goodbye. Trends Pharmacol. Sci., 19, 311-316.
26. 1B D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn-Schmiedeherg's Arch. Pharmacol. 355, 295-302.
27. 1D receptor agonists in development for the acute treatment of migraine. In Headache treatment: trial methodology and new drugs. eds. Olesen, J. & Tfelt-Hansen, P., pp. 229-241. New York: Lippincott-Raven Publishers.
28. Saxena, P.R., Schamhardt, H.C., Forsyth, R.P. & Loeve, J. (1980). Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput. Programs Biomed., 12, 63-84.
29. Saxena, P.R., & Verdouw, P.D. (1982). Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J. Physiol., 332, 501-520.
30. Saxena, P.R. & Villalón, C.M. (1990). Cardiovascular effects of serotonin agonists and antagonists. J. Cardiovasc. Pharmacol., 15, S17-34.
31. 1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto-and heteroreceptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 356, 321-327.
32. 1D agonist. Br. J. Clin. Pharmacol., 43, 49-54.
33. Seaber, E., On, N., Phillips, S., Churchus, R., Posner, J. & Rolan, P. (1996). The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br. J. Clin. Pharmacol., 41, 141-147.
34. 1B receptor antagonist with negative intrinsic activity. Br. J. Pharmacol., 125, 202-208.
35. 1D receptor antagonist. Behav. Brain Res., 73, 157 - 161.
36. Steel, R.G.D. & Torrie, J.H. (1980). Principles and procedures of statistics. A biomedical approach (2nd edition), Tokyo: McGraw-Hill Kogakusha Ltd.
37. Ullmer, C., Schmuck, K., Kalkman, H.O., & Lübbert, H. (1995). Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett., 370, 215-221.
38. Verdouw, P.D., Duncker, D.J. & Saxena, P.R. (1984). Poor vasoconstrictor response to adrenergic stimulation in the arteriovenous anastomoses present in the carotid vascular bed of young Yorkshire pigs. Arch. Int. Pharmacodyn. Ther., 272, 56-70.
39. 1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br. J. Pharmacol., 124, 1345-1354.
40. 1D subtypes. Br. J. Pharmacol., 124, 1001-1011.
41. Z-adrenoceptors. Br. J. Pharmacol., 126, 585-594.
42. Villalón, C.M., Ramirez-San Juan, E., Castillo, C., Castillo, E., Lopez-Munoz, F.J. & Terrón, J.A. (1995). Pharmacological profile of the receptors that mediate external carotid vasoconstriction by 5-HT in vagosympathectomized dogs. Br. J. Pharmacol., 116, 2778-2784.
43. 1D receptor subtype. Naunyn-Schmiedeberg's Arch. Pharmacol., 354, 550-556.
44. 1Dβ. Proc. Natl. Acad. Sci. U.S.A., 89, 3630-3634.
45. 1B 1D receptor agonist with anti-migraine activity. Naunyn-Schmiedeberg's Arch. Pharmacol., 358, 212-219.